At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 125 enrolled
Drug / intervention
Immunotherapeutic GSK2132231Abiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
GSK2132231A Antigen-Specific Cancer Immunotherapeutic as First-line Treatment of Patients With Unresectable Metastatic Melanoma
In Brief
A Phase 2 clinical trial evaluating Immunotherapeutic GSK2132231A for Melanoma. Completed, enrolled 125 participants across 63 sites in 8 countries.
Detailed Summary
The objective of this study is to evaluate the clinical activity of the GSK2132231A immunotherapeutic in patients with MAGE-A3 positive unresectable metastatic melanoma presenting with the predictive gene signature.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMelanoma
CountriesFrance, Germany, Ireland, Italy, Poland, Russia, Spain, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedJul 2009
Enrollment StartAug 2009
Primary CompletionJun 2012
Study CompletionApr 2015
TodayJul 2026
First PostedJul 20, 2009
Enrollment StartAug 14, 2009
Primary CompletionJun 27, 2012
Study CompletionApr 1, 2015
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 16.9 years ago
Interventions
Immunotherapeutic GSK2132231Abiological
Intramuscular administration